Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Or Neurotransmitter (e.g., Insulin, Human Chorionic Gonadotropin, Intragonadal Regulatory Protein, Mullerian Inhibiting Substance, Inhibin, Epidermal Growth Factor, Nerve Growth Factor, Dopamine, Norepinephrine, Etc.) Patents (Class 530/388.24)
-
Patent number: 8236307Abstract: The present invention concerns antagonists of the FGF19/FGFR4 pathways, and the uses of same.Type: GrantFiled: August 1, 2008Date of Patent: August 7, 2012Assignee: Genentech, Inc.Inventors: Mark Dennis, Luc Desnoyers, Dorothy French
-
Patent number: 8226951Abstract: The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.Type: GrantFiled: June 6, 2011Date of Patent: July 24, 2012Assignee: Pfizer Inc.Inventors: David L. Shelton, Patrick William Mantyh
-
Patent number: 8221749Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: GrantFiled: July 29, 2011Date of Patent: July 17, 2012Assignee: Amgen Inc.Inventors: Thomas C. Boone, Jonathan D. Oliner
-
Patent number: 8216571Abstract: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.Type: GrantFiled: October 20, 2008Date of Patent: July 10, 2012Assignee: Schering CorporationInventors: Sumant Ramachandra, Walter Robert Bishop, Linda Masat, Chao Bai Huang, Toshihiko Takeuchi, Seema Kantak, Chin-Yi Huang
-
Patent number: 8216583Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.Type: GrantFiled: August 15, 2003Date of Patent: July 10, 2012Assignee: Abbott Biotechnology, Ltd.Inventors: Hans-Juergen Kruase, Lisa Baust, Michael Dickes
-
Publication number: 20120171217Abstract: Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.Type: ApplicationFiled: December 8, 2011Publication date: July 5, 2012Applicant: LEXICON PHARMACEUTICALS, INC.Inventors: E-Chiang Lee, Gregory M. Landes, Kyu Chung, Ling Chen, Urvi Desai, David Reed Powell, Seokjoo Hong
-
Patent number: 8207307Abstract: Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases.Type: GrantFiled: June 3, 2010Date of Patent: June 26, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Hendrik Knoetgen, Hans-Willi Krell, Sandra Miller, Jens Niewoehner, Dirk Ponsel, Engin Toksoez
-
Patent number: 8198410Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.Type: GrantFiled: November 25, 2008Date of Patent: June 12, 2012Assignee: Amgen Inc.Inventors: Kenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
-
Publication number: 20120141495Abstract: The invention pertains to the field of medicine, particularly to methods for suppressing the growth of tumors, which comprise blocking the pathological pathway of human fibroblast growth factor/receptor 1 (domains II and IIIc), and for diagnosing malignant neoplasms leading to an excessive proliferation of tumor cells and to the formation of new vessels accompanied by the growth of primary tumors and metastases. This pathway also represents an independent mechanism of tumor resistance to preparations acting on other pathological pathways. Blocking the aforementioned pathway using various substances that neutralize the receptor by bonding only with domains II and IIIc thereof results in the interruption or slow-down of tumor growth. This receptor can also be used as a target for delivery of diagnostic agents being largely present in tumor cells. The invention enables developing new agents for diagnosing and treating diseases related to excessive proliferation and neovascularization.Type: ApplicationFiled: June 30, 2009Publication date: June 7, 2012Inventor: Ilya Valer'evich Tsimafeyeu
-
Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
Patent number: 8173781Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.Type: GrantFiled: June 30, 2009Date of Patent: May 8, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki -
Patent number: 8168761Abstract: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.Type: GrantFiled: February 18, 2011Date of Patent: May 1, 2012Assignee: Stowers Institute for Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Patent number: 8168762Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.Type: GrantFiled: October 3, 2011Date of Patent: May 1, 2012Assignee: Amgen Inc.Inventors: Simon Mark Jackson, Bei Shan, Wenyan Shen, Chadwick Terence King
-
Patent number: 8158752Abstract: The objects of the present invention are: to provide a therapeutic agent and a therapeutic method for periodontal diseases and pulpal diseases, a transplant for periodontal tissue regeneration, and a method for regenerating the periodontal tissue. According to the present invention, there are provided therapeutic agents for periodontal diseases and pulpal diseases which comprise neurotrophic factors as an active ingredient.Type: GrantFiled: September 8, 2004Date of Patent: April 17, 2012Assignees: Two Cells Co., Ltd.Inventors: Hidemi Kurihara, Hiroyuki Kawaguchi, Katsuhiro Takeda, Hideki Shiba, Noriyoshi Mizuno, Hiroshi Yoshino, Naohiko Hasegawa, Hiroaki Shinohara
-
Patent number: 8133981Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.Type: GrantFiled: March 10, 2009Date of Patent: March 13, 2012Assignee: Abbott Biotherapeutics Corp.Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
-
Patent number: 8133979Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: December 11, 2009Date of Patent: March 13, 2012Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
-
Publication number: 20120058052Abstract: The invention relates to a method and apparatus for pre-hatch avian embryo sex determination. In particular, the invention relates to a non-invasive method and apparatus for in-ovo determining the sex of avian species while in the egg and allowing to sort the eggs into groups consisting primarily of either male or female embryos. The method comprises the steps of introducing into the egg an antibody designed to match with a sex specific antigen on the embryo, which antibody is labelled, allowing the labelled antibody to migrate to and bind with the sex specific antigen on the embryo, detecting binding of the labelled antibodies on the embryo using detection means positioned outside of the egg.Type: ApplicationFiled: March 12, 2010Publication date: March 8, 2012Applicant: PRINZEN B.V.Inventors: Eddy Decuypere, Frank Fey
-
Publication number: 20120052596Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.Type: ApplicationFiled: May 6, 2010Publication date: March 1, 2012Applicants: Otsuka Pharmaceutical Co., Ltd., Mitsubishi Chemical Medience CorporationInventors: Suguru Akamatsu, Kiyonori Katsuragi, Hideaki Onishi, Midori Abe, Toru Hadama, Ayako Nishimura, Mio Ooguchi
-
Patent number: 8119134Abstract: A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity.Type: GrantFiled: August 3, 2010Date of Patent: February 21, 2012Assignee: Glenveigh Pharmaceuticals, LLCInventor: Charles David Adair
-
Patent number: 8105598Abstract: Disclosed herein are isolated monoclonal human antibodies that specifically binds insulin-like growth factor II (IGF-II) with an equilibrium dissociation constant (Kd) of 1 nM or less, wherein the antibody bind IGF-I with an equilibrium dissociation constant (Kd) of 1 mM or greater. The antibodies inhibit phosphorylation of the insulin-like growth factor receptor. Nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and isolated host cells that express the nucleic acids are also disclosed. The antibodies can be used to detect human IGF-II in a sample. Methods of diagnosing a tumor are disclosed herein that utilize these antibodies. Methods of treating a subject with a tumor are also disclosed.Type: GrantFiled: September 23, 2010Date of Patent: January 31, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Yang Feng
-
Patent number: 8106164Abstract: The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils.Type: GrantFiled: June 21, 2005Date of Patent: January 31, 2012Assignee: BioArctic Neuroscience ABInventors: Pär Gellerfors, Lars Lannfelt
-
Patent number: 8106166Abstract: The present invention relates to a purified molecules, including antibodies, that bind specifically to murine ?-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.Type: GrantFiled: March 17, 2008Date of Patent: January 31, 2012Assignee: Stowers Institute for Medical ResearchInventors: Xi He, Tong Yin, Qiang Tian, Weiguo Tao, Leroy Hood, Linheng Li
-
Patent number: 8106167Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of these antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.Type: GrantFiled: August 18, 2010Date of Patent: January 31, 2012Assignee: Amgen Inc.Inventors: Kenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
-
Patent number: 8106165Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: GrantFiled: May 8, 2007Date of Patent: January 31, 2012Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Craig A. Rosen, Guo-Liang Yu, Jian Ni, Ping Feng
-
Patent number: 8101725Abstract: The present invention is directed toward a neutralizing monoclonal antibody to basic fibroblast growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.Type: GrantFiled: May 28, 2009Date of Patent: January 24, 2012Assignee: Galaxy Biotech, LLCInventors: Kyung Jin Kim, Lihong Wang, Hangil Park, Maximiliano Vasquez
-
Patent number: 8097252Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: January 6, 2011Date of Patent: January 17, 2012Assignee: Immunomedics, Inc.Inventors: William J. McBride, Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen
-
Patent number: 8088898Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.Type: GrantFiled: March 3, 2009Date of Patent: January 3, 2012Assignee: Abbott Biotherapeutics Corp.Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
-
Publication number: 20110319327Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.Type: ApplicationFiled: April 27, 2011Publication date: December 29, 2011Applicant: Genentech, Inc.Inventors: Napoleone Ferrara, Sophia S. Kuo
-
Publication number: 20110311546Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: June 9, 2011Publication date: December 22, 2011Inventors: Jonathan Daniel Oliner, Kevin Graham
-
Publication number: 20110300068Abstract: The present invention provides an agent for the prophylaxis or treatment of kidney cancer or urinary bladder cancer, and a diagnostic reagent for these cancers which comprise an antibody against nerve growth factor 2/neurotrophin-3 or a partial peptide thereof or a salt thereof, which antibody neutralizes nerve growth factor 2/neurotrophin-3 and does not cross-react with the Nerve Growth Factor.Type: ApplicationFiled: January 12, 2010Publication date: December 8, 2011Applicant: Takeda Pharmaceutical Company LimitedInventors: Tatsuya Watanabe, Shinichi Kondo, Ryosuke Katsuyama
-
Patent number: 8071323Abstract: Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided.Type: GrantFiled: April 6, 2007Date of Patent: December 6, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu
-
Patent number: 8071733Abstract: The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G?CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described.Type: GrantFiled: May 28, 2010Date of Patent: December 6, 2011Assignees: The Johns Hopkins University School of Medicine, University of WashingtonInventors: Philip A. Beachy, Jeffrey A. Porter, Randall T. Moon
-
Publication number: 20110281801Abstract: The present disclosure relates to methods for detecting an increased risk of preeclampsia, determining the presence of preeclampsia, reducing the likelihood that preeclampsia will develop and treating preeclampsia. It also provides methods of measuring relaxin levels in a biological sample of a pregnant woman.Type: ApplicationFiled: November 24, 2009Publication date: November 17, 2011Applicant: University of Pittsburgh-Of the Comonwealth SystemInventors: Dennis Stewart, Kirk P. Conrad, Arundhathi Jeyabalan
-
Patent number: 8058418Abstract: Compositions comprising polynucleotides encoding heavy and light chains of antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of making such antibodies are described.Type: GrantFiled: October 30, 2007Date of Patent: November 15, 2011Assignees: Amgen Inc., Amgen Fremont Inc.Inventors: William J. Boyle, Francis H. Martin, Jose R. Corvalan, C. Geoffrey Davis
-
Patent number: 8048417Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.Type: GrantFiled: September 17, 2008Date of Patent: November 1, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: De Santis Rita, Anastasi Anna Maria
-
Patent number: 8048635Abstract: Methods of treating patients and evaluating patients for disease stage and/or severity are disclosed.Type: GrantFiled: December 10, 2007Date of Patent: November 1, 2011Assignees: Biogen Idec MA Inc., Albert Einstein College of Medicine of Yeshiva UniversityInventors: Linda C. Burkly, Jennifer Michaelson, Chaim Putterman
-
Patent number: 8043620Abstract: The present invention relates to binding agents for WISE, and includes for their manufacture and use.Type: GrantFiled: November 21, 2008Date of Patent: October 25, 2011Assignee: Amgen Inc.Inventors: Xueming Qian, Kevin Graham, Grant Shimamoto, Barbara S. Tipton, Mei-Mei Tsai, Aaron George Winters, Li Zhang
-
Publication number: 20110256554Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: ApplicationFiled: June 1, 2011Publication date: October 20, 2011Inventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 8038997Abstract: Described herein are deposited hybridoma cell lines and the monoclonal antibodies produced by these hybridomas, and antigen binding fragments thereof. These monoclonal antibodies and antigen binding fragments specifically bind marinobufagenin. The disclosure also encompasses the use of these monoclonal antibodies or antigen binding fragments in a method for detecting the presence of marinobufagenin in a biological sample. Also provided are methods for the use of these monoclonal antibodies or antigen binding fragments as prophylactic, therapeutic, and diagnostic agents for the detection, inhibition and treatment of a cardiovascular disease, for example, essential hypertension, hypertension associated with preeclampsia, eclampsia, or renal failure, or myocardial fibrosis in a subject.Type: GrantFiled: June 26, 2006Date of Patent: October 18, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Alexei Bagrov, Olga V. Fedorova, Edward G. Lakatta, Andrey Simbirtsev, Alexander Kotov, Nikolai Kolodkin
-
Patent number: 8034346Abstract: The present invention features methods for treating or preventing pain comprising administering an amount of a nerve growth factor antagonist (such as an anti-NGF antibody) and an amount of an NSAID such that together they provide effective pain relief. The invention also features compositions comprising a nerve growth factor antagonist and an NSAID and kits containing the same.Type: GrantFiled: December 22, 2009Date of Patent: October 11, 2011Assignee: Rinat Neuroscience Corp.Inventors: David L. Shelton, German J. Vergara, Carole M. Loo
-
Patent number: 8030456Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.Type: GrantFiled: December 15, 2008Date of Patent: October 4, 2011Assignees: Yale University, Biogen Idec MA Inc.Inventors: Daniel H. S. Lee, R. Blake Pepinsky, Weiwei Li, Jane K. Relton, Dane S. Worley, Stephen M. Strittmatter, Dinah W. Y. Sah, Sylvia A. Rabacchi
-
Patent number: 8030457Abstract: Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.Type: GrantFiled: August 22, 2008Date of Patent: October 4, 2011Assignee: Amgen, Inc.Inventors: Simon Mark Jackson, Bei Shan, Wenyan Shen, Chadwick Terence King
-
Patent number: 8025881Abstract: When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix.Type: GrantFiled: July 19, 2007Date of Patent: September 27, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Toshio Doi, Hideharu Abe, Naoshi Fukushima, Hitoshi Tai, Takakazu Mizuno, Masahiko Kinosaki
-
Patent number: 8017734Abstract: The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. In particular, the method determining the level of two or more markers selected from placenta growth factor (PlGF), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor-2 (PAI-2) and leptin.Type: GrantFiled: September 15, 2008Date of Patent: September 13, 2011Assignee: PerkinElmer LAS, Inc.Inventors: Lucilla Poston, Paul Townsend Seed, Beverley Jane Hunt, Lucy Charlotte Chappell
-
Patent number: 8017748Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.Type: GrantFiled: April 18, 2006Date of Patent: September 13, 2011Assignee: Micromet AGInventors: Tobias Raum, Julia Hepp (Nee Henckel), Eva Vieser (Nee Krinner), Silke Petsch (Nee Mittelstrass), Steven Zeman, Andreas Wolf, Sandra Bruckmaier
-
Patent number: 8012482Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.Type: GrantFiled: April 14, 2009Date of Patent: September 6, 2011Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Napoleone Ferrara, Ellen Filvaroff, Weiguang Mao, Leonard G. Presta, Max L. Tejada
-
Publication number: 20110212088Abstract: Monoclonal antibodies to platelet activating factor (PAF) are described, along with methods for their production and use. Such antibodies can be formulated and used for therapeutic purposes, as well as for diagnosis and detection.Type: ApplicationFiled: February 25, 2011Publication date: September 1, 2011Inventors: Roger A. SABBADINI, Jonathan Michael WOJCIAK
-
Patent number: 8007800Abstract: The invention features methods and compositions for preventing or treating bone cancer pain including cancer pain associated with bone metastasis by administering an antagonist of nerve growth factor (NGF). The NGF antagonist may be an anti-NGF (such as anti-hNGF) antibody that is capable of binding hNGF.Type: GrantFiled: March 16, 2009Date of Patent: August 30, 2011Assignee: Pfizer Inc.Inventors: David L. Shelton, Patrick William Mantyh
-
Patent number: 8008448Abstract: The present application discloses monoclonal antibody against cotinine and nicotine.Type: GrantFiled: March 14, 2008Date of Patent: August 30, 2011Assignee: National Cancer CenterInventors: Sunyoung Park, Junho Chung, Dohoon Lee, Jae-Gahb Park
-
Patent number: 8008450Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.Type: GrantFiled: November 2, 2009Date of Patent: August 30, 2011Assignee: Abbott Biotherapeutics Corp.Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
-
Patent number: RE43497Abstract: The present invention relates to methods for screening molecules and methods to detect protein-protein interactions and means used therein. More specifically, the present invention relates to methods for screening candidate drugs for treating or detecting MIF (macrophage migration inhibitor factor) related diseases. In certain aspects, the present invention involves detecting MIF/Jab1 (c-Jun activation domain binding protein) interactions as a basis for modulating cellular regulatory pathways and for identifying candidate drugs for MIF-related diseases. The invention also provides methods for the identification of molecules which dissociate or prevent interaction or binding between MIF and Jab1.Type: GrantFiled: November 2, 2000Date of Patent: June 26, 2012Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.Inventors: Herwig Brunner, Jürgen Bernhagen, Robert Kleemann, Ralf Mischke, Afroditi Kapurniotu